ANALYSIS OF BLOOD SAMPLES TO DETECT TAUPATHY OR AMYLOIDOGENIC DISEASE
Patent Information
- Application Number
- EA202590522
- Authority / Receiving Office
- EA · EA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-03-04
- Filing Date
- 2021-07-14
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2041-07-14
Smart Images

Figure 00000041_0000 
Figure 00000041_0001 
Figure 00000042_0000
Abstract
Claims
1. An analytical method for detecting p217+ tau peptides in a subject, wherein The method includes the following steps: (a) obtain a plasma sample from the subject; (b) contacting the plasma sample with a capture antibody directed to an epitope comprising amino acids 210-220 of human tau protein to bind the capture antibody to p217+tau peptides in the plasma sample to form antibody-peptide complexes; (c) wash the antibody-peptide complexes; (d) contacting the antibody-peptide complexes with a detector antibody directed to an epitope comprising amino acids 7-20 of human tau protein to bind the detector antibody to the antibody-peptide complexes; and (e) A detection antibody is detected to determine the amount of p217+ tau peptides in the plasma sample.
2. The method according to claim 1, wherein the capture antibody is immobilized on a solid phase.
3. The method according to claim 2, wherein the solid phase is a magnetic granule.
4. A method for detecting tauopathy in a subject, the method comprising the steps of: (a) obtain a plasma sample from the subject; (b) detecting an amount of p217+tau peptides in a plasma sample by an assay, wherein the assay comprises using a capture antibody directed to an epitope comprising amino acids 210-220 of human tau protein to bind the capture antibody to p217+tau peptides in the plasma sample to form antibody-peptide complexes, and a detector antibody directed to an epitope comprising amino acids 7-20 of human tau protein to bind the detector antibody to the antibody-peptide complexes; and (c) determining whether a subject has a tauopathy or is at risk of developing a tauopathy when the amount of p217+ tau peptides is above a predetermined threshold, wherein the predetermined threshold is greater than the lower limit of quantification (LLOQ) of the assay.
5. A method for detecting an amyloidogenic disease in a subject, wherein the method comprises the steps of: (a) obtain a plasma sample from the subject; (b) detecting an amount of p217+tau peptides in a plasma sample by an assay, wherein the assay comprises using a capture antibody directed to an epitope comprising amino acids 210-220 of human tau protein to bind the capture antibody to p217+tau peptides in the plasma sample to form antibody-peptide complexes and a detector antibody directed to an epitope comprising amino acids 7-20 of human tau protein to bind the detector antibody to the antibody-peptide complexes; and (c) determining whether a subject has an amyloidogenic disease or is at risk of developing an amyloidogenic disease when the amount of p217+ tau peptides is above a predetermined threshold, wherein the predetermined threshold is greater than the lower limit of quantification (LLOQ) of the assay.
6. The method according to claim 4 or 5, wherein the analysis does not concentrate p217+tau peptides from the plasma sample by immunoprecipitation before measuring the amount of p217+tau peptides present.
7. The method according to any one of claims 4 to 6, wherein the LLOQ corresponds to a coefficient of variation (CV) of the assay of 15-25%.
8. The method according to claim 7, wherein the LLOQ corresponds to a CV of the assay of 20%.
9. The method according to any one of claims 4 to 8, wherein the specified threshold value is at least 3 times greater than the LLOQ.
10. The method of claim 9, wherein the predetermined threshold value is at least 10 times the lower limit of quantification of the assay.
11. The method according to claim 5, wherein the amyloidogenic disease is Alzheimer's disease.
12. A method for detecting or predicting tauopathy in a subject, the method comprising the steps of: (a) detecting an amount of p217+tau peptides in a plasma sample by contacting the plasma sample with a capture antibody directed to an epitope comprising amino acids 210-220 of human tau protein to bind the capture antibody to p217+tau peptides in the plasma sample to form antibody-peptide complexes and separately contacting the antibody-peptide complexes with a detector antibody directed to an epitope comprising amino acids 7-20 of human tau protein to bind the detector antibody to the antibody-peptide complexes; (b) generate tau data corresponding to the number of p217+tau peptides detected; (c) obtaining biomarker data corresponding to at least one biomarker determined in the subject, wherein the biomarker is selected from the group comprising neurofilament light chain (NFL), adiponectin, and leptin; and (d) comparing the tau protein data and additional biomarker data with a reference data set using a machine learning module to determine or predict whether the subject has a tauopathy or is at risk of developing a tauopathy.
13. The method of claim 12, wherein the machine learning module comprises at least one of a support vector machine module, a random forest module, a logistic regression module, and a gradient boosting module.
14. The method according to claim 4 or 12, in which the tauopathy is selected from the group consisting of familial Alzheimer's disease, sporadic Alzheimer's disease, frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy, corticobasal degeneration, Pick's disease, progressive subcortical gliosis, dementia with predominant neurofibrillary tangles, diffuse neurofibrillary tangles with calcification, dementia with argyrophilic grains, amyotrophic lateral sclerosis-parkinsonism-dementia complex, Down syndrome, Gerstmann-Sträussler-Scheinker disease, Hallervorden-Spatz disease, inclusion body myositis, Creutzfeldt-Jakob disease, multiple system atrophy, Niemann-Pick type C, cerebral amyloid angiopathy with prion proteins, subacute sclerosing panencephalitis, myotonic dystrophy, non-Guam motor neuron disease with neurofibrillary tangles, postencephalitic parkinsonism,chronic traumatic encephalopathy and dementia pugulistica (boxer's dementia).
15. The method of claim 14, wherein the tauopathy is Alzheimer's disease.
16. The method of claim 14, wherein the tauopathy is progressive supranuclear palsy.
17. The method according to any one of claims 1 to 16, wherein the capture antibody comprises immunoglobulin heavy chain complementarity determining regions (HCDR)-1, HCDR2 and HCDR3, respectively, having the polypeptide sequences of SEQ ID NOs: 23, 24 and 25, and immunoglobulin light chain complementarity determining regions (LCDR)-1, LCDR2 and LCDR3, respectively, having the polypeptide sequences of SEQ ID NOs: 26, 27 and 28.
18. The method according to any one of claims 1 to 17, wherein the capture antibody is pT3.
19. The method according to any one of claims 1 to 18, wherein the detector antibody comprises immunoglobulin heavy chain complementarity determining regions (HCDR)-1, HCDR2 and HCDR3, respectively, having the polypeptide sequences of SEQ ID NOs: 10, 11 and 12, and immunoglobulin light chain complementarity determining regions (LCDR)-1, LCDR2 and LCDR3, respectively, having the polypeptide sequences of SEQ ID NOs: 13, 14 and 15.
20. The method according to any one of claims 1 to 19, wherein the detector antibody is hT43.
